Document is current
Any future updates will be listed below
-
Authors
Tihaya, Mara S. https://orcid.org/0000-0002-0608-6023
Mul, Karlien
Balog, Judit
de Greef, Jessica C. https://orcid.org/0000-0002-2819-6098
Tapscott, Stephen J.
Tawil, Rabi
Statland, Jeffrey M.
van der Maarel, Silvère M. https://orcid.org/0000-0001-8103-711X
- License Information
-
More Information
Article History
Accepted: 7 December 2022
First Online: 10 January 2023
Competing interests
: K.M. declares that she has acted as a consultant for Avidity Biosciences. S.J.T. declares that he has acted as a consultant for Avidity Biosciences and is a Board member for Renogenyx. R.T. declares that he has acted as a consultant and/or is a member of the advisory board for Arrowhead Pharma, Avidity Biosciences, Dyne Therapeutics, Fulcrum Therapeutics, Mitsubishi Tanabe Pharma, miRecule Biotech and Roche. J.M.S. declares that he has acted as a consultant and/or is a member of the advisory board for Acceleron, Avidity Biosciences, Dyne Therapeutics, Fulcrum Therapeutics, Ionis, ML Bio Solutions, Mitsubishi Tanabe Pharma, Roche and Sarepta. S.M.v.d.M. declares that he has acted as consultant and/or is a member of the advisory board for Avidity Biosciences, Dyne Therapeutics and Fulcrum Therapeutics and is a Board member for Renogenyx. The other authors declare no competing interests.
